BioLineRx Ltd. (NASDAQ: BLRX) has initiated a first-in-human Phase 1/2a clinical trial of GLIX1 for treating recurrent and progressive glioblastoma ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE